Skip to main content

AMAG Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced Louis Brenner MD, Senior Vice President and David Arkowitz, Chief Financial Officer and Chief Business Officer, will present an overview of the Company at the Morgan Stanley Global Healthcare Unplugged Conference on Thursday, May 1 at 8:40 a.m. ET. The conference is being held April 30 May 2, 2008 in Key Biscayne, FL.

A live audio webcast of the presentation will be accessible through the Investors section of the Companys website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until May 15, 2008.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Companys key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration (FDA) in December 2007, which was accepted for filing by the FDA in February 2008.

Contacts:

AMAG Pharmaceuticals, Inc.
Kristen Galfetti, 617-498-3362
kgalfetti@amagpharma.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.